Back

SGLT2 inhibitors and alteration of substrate metabolism.

27 August 2018 (12:07 - 12:30)
Organised by:
Congress Presentation Part of: How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease? Diabetes and the Heart ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Ele Ferrannini

CNR – National Research Council, Pisa (Italy)

3 More presentations in this session

Presentation thumbnail
Epigenetic signatures and cardiovascular risk in diabetes.
Professor F. Cosentino (Stockholm, SE)
Presentation thumbnail
Use of incretin-based therapies.
Professor L. Ryden (Stockholm, SE)
Slides Video
Presentation thumbnail
Mechanisms of cardiovascular impact of SGLT2 inhibitors.
Professor B. Staels (Lille Cedex, FR)
Slides Video

Access the full session

Session thumbnail
How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease?

The Event

Event poster

ESC Congress 2018

27 August 2018 12:07 CET
You may be interested in
thumbnail
Webinar
Prevention of heart failure in diabetic patients at population level
thumbnail
Congress Session
Diabetes, obesity, and heart failure
thumbnail
Webinar
Diabetes and ACS - enhancing post-discharge outcomes after primary PCI

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources